Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$10.7B
71M shares
52-week range
$122.00 – $200.44
39% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
P/S (TTM)
2.6
EV / FCF (TTM)
13.2
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
www.aligntech.comNo one on the platform currently holds ALGN.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 9,923 | $1.7M |
| Renaissance Technologiesas of 2025-06-30 | 2,100 | $397.6K |
No one on the platform has traded ALGN yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.0% | 17.2% | 34.5% | — | — | — |
| Rev. Growth % | 0.9% | 10.3% | ||||
| Profit Margin % | 10.2% | 12.3% | 20.5% | |||
| Free Cash Flow Margin % | 12.2% | 14.1% | 16.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +2.2% on the P/E track.
At today's price, your expected annual return is +7.3% on the P/E track.
At today's price, your expected annual return is +11.9% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.2B | +3.6% | $11.29 | $11.11–$11.68 | 13.5× | 10 |
| 2027 | $4.3B | +4.0% | $12.54 | $12.22–$12.85 | 12.2× | 10 |
| 2028 | $4.6B | +5.2% | $13.78 | $12.43–$15.38 | 11.1× | 5 |
| 2029 | $4.9B | +6.4% | $15.35 | $15.10–$15.66 | 10.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $2.62 | $2.64 | +0.8% |
| 2026-04-29 | $2.30 | $2.58 | +12.2% |
| 2026-02-04 | $2.99 | $3.29 | +10.0% |
| 2025-10-29 | $2.40 | $2.61 | +8.8% |
| 2025-07-30 | $2.57 | $2.49 | -3.1% |
| 2025-04-30 | $1.99 | $2.13 | +7.0% |
| 2025-02-05 | $2.43 | $2.44 | +0.4% |
| 2024-10-23 | $2.31 |
| $2.35 |
| +1.7% |
| $14.1B |
| — |
| GMEDGlobus Medical, Inc. | $75.77 | +2.13% | $10.2B | — |
| HIMSHims & Hers Health, Inc. | $28.81 | +4.73% | $6.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
The Stealth Bear Market: What Most Investors Missed $VZ $ALGN $AMT $NKE $PYPL https://talkmarkets.com/article/the-stealth-bear-market-what-most-investors-missed-1788635159
View on StockTwits ↗
$ALGN "Align Technology, Inc. (ALGN) holds a consensus "Moderate Buy" rating among Wall Street analysts, carrying a median 12-month price target of $206.36 to $209.00. This reflects a forecasted upside of approximately 30% from its recent trading price of $158.34. The stock is currently trading toward the lower-middle portion of its 52-week range of $122.00 to $200.25. International Expansion: Strong double-digit volume growth across APAC, EMEA, and Latin America. Market Dominance: Holds a dominant 90% share of the global clear aligner market with its Invisalign brand. Digital Ecosystem: Active intraoral iTero scanner placements expanded double digits to onboard more doctors. Long-term Outlook: Long-term annual earnings growth is forecast to average roughly 16% to 34% over the next few years." HOLDING
View on StockTwits ↗
$ALGN if 📉 $130, will take in a terrible market’s month of September.
View on StockTwits ↗
$ALGN literally everything in this market is up but this - i dont get it - im not leaving but cmon
View on StockTwits ↗
Top pre-market gainers & losers (S&P 500) 📈📉 $NDSN $ALGN $HOOD $WMT $MRNA
View on StockTwits ↗$ALGN "The 12-month outlook for Align Technology, Inc. (NASDAQ: ALGN) is moderately bullish with a split investment case. Strong double-digit international expansion for its core Invisalign product line is acting as a major growth engine, but it is currently being offset by a slump in expensive dental equipment spending and recent tax headwinds in Europe. On August 17, 2026, Align secured a massive legal victory in China, winning a major patent infringement lawsuit against Angelalign Technology's subsidiaries, effectively safeguarding its competitive moat. Trading near 16x forward earnings, ALGN is considered structurally undervalued by roughly 19% to 41% against long-term intrinsic value models (GF Value, DCF models) and key global dental competitors."
View on StockTwits ↗
$ALGN right shoulder just formed on the weekly. Above the 9, 20 and 50 MAs. Really like this one.
View on StockTwits ↗
$ALGN Align Technology Prevails in China Patent Infringement Action Against Angelalign "today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel")"
View on StockTwits ↗$ALGN bulls are starting to fight here on the monthly chart
View on StockTwits ↗
$ALGN "Align Technology (NASDAQ: ALGN), the maker of Invisalign clear aligners, recently reported its Q2 2026 financial results, delivering a mixed outlook that showcases robust core volume growth and operational margin expansion offset by softness in its dental imaging equipment segment and weaker-than-expected short-term guidance. While Align slightly beat Q2 consensus estimates with record revenue of $1.06 billion (up 4.3% YoY) and adjusted EPS of $2.64, the stock dipped into the $175 range due to a conservative Q3 forecast and a looming UK tax liability. Market analysts remain generally optimistic on Align's long-term digital platform ecosystem despite the near-term capital equipment slowdown. The current consensus points to a Moderate Buy, with trailing 12-month price targets averaging between $206 and $214, implying an estimated upside potential of 15% to 22% from current price positions." HOLD
View on StockTwits ↗
Digital dentistry is becoming a platform race. Align, Envista, and Dentsply Sirona are all competing to build connected ecosystems spanning imaging, AI, treatment planning, and clinical workflows — not just individual products. Align faces an Elliott-backed strategic review. Envista and Dentsply report earnings next week. https://prismmarketview.com/digital-dentistrys-next-phase-is-about-platforms-not-products/ $ALGN $XRAY $NVST #dentalcare #dentistry #algn #nvst #DigitalDentistry
View on StockTwits ↗
@cynicaloptimist @Jblack500 @BustaCapital @IsabellaDC @WAJeff @No_Face_character $ALGN - crooked teeth
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.